score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.6316	152.0	1.6e-05	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0.0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	0	4.0	0.0	0.161	BRAF p.V600E (Missense)	1.0	MEL-IPI_Pat02	MEL-IPI_Pat02-Tumor-SM-4DJZX	MEL-IPI_Pat02-Normal-SM-4NFU4
Investigate Actionability	Guideline			Rearrangement	COL1A1	Fusion	COL1A1--CITED4			0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Imatinib has shown clinical activity against localized and metastatic DFSP tumors containing t(17;22)(q22;q13).	National Comprehensive Cancer Network. Dermatofibrosarcoma NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/dfsp_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/dfsp_blocks.pdf													0				COL1A1--CITED4 Fusion	0.0	MEL-IPI_Pat02		
Investigate Actionability			Inferential	Aneuploidy	Whole genome doubling																						Investigate Actionability	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						MEL-IPI_Pat02		
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Missense	p.D887N	0.8039	51.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596													0	0.0	0.0	0.0	MSH2 p.D887N (Missense)		MEL-IPI_Pat02	MEL-IPI_Pat02-Tumor-SM-4DJZX	MEL-IPI_Pat02-Normal-SM-4NFU4
Investigate Actionability			Guideline	Somatic Variant	ZRSR2	Missense	p.N261I	0.4019	107.0	0.0	0.0																Investigate Actionability	0.0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	29.0	0.0	0.9987	ZRSR2 p.N261I (Missense)		MEL-IPI_Pat02	MEL-IPI_Pat02-Tumor-SM-4DJZX	MEL-IPI_Pat02-Normal-SM-4NFU4
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.F467I	0.3571	56.0	0.0	0.0																Investigate Actionability	0.0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	27.0	0.0	0.9881	STAG2 p.F467I (Missense)		MEL-IPI_Pat02	MEL-IPI_Pat02-Tumor-SM-4DJZX	MEL-IPI_Pat02-Normal-SM-4NFU4
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.G674E	0.4	40.0	0.0	0.0																					0	222.0	0.0	1.0	PDGFRB p.G674E (Missense)		MEL-IPI_Pat02	MEL-IPI_Pat02-Tumor-SM-4DJZX	MEL-IPI_Pat02-Normal-SM-4NFU4
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.H300Y	0.6136	44.0	0.0	0.0																					0	17.0	0.0	0.9982	NTRK2 p.H300Y (Missense)		MEL-IPI_Pat02	MEL-IPI_Pat02-Tumor-SM-4DJZX	MEL-IPI_Pat02-Normal-SM-4NFU4
Biologically Relevant				Copy Number	EWSR1	Amplification				0.0	0.0																					0				EWSR1 Amplification		MEL-IPI_Pat02	MEL-IPI_Pat02-Tumor-SM-4DJZX	
Biologically Relevant				Copy Number	CTNNB1	Amplification				0.0	0.0																					0				CTNNB1 Amplification		MEL-IPI_Pat02	MEL-IPI_Pat02-Tumor-SM-4DJZX	
Biologically Relevant				Copy Number	BLM	Amplification				0.0	0.0																					0				BLM Amplification		MEL-IPI_Pat02	MEL-IPI_Pat02-Tumor-SM-4DJZX	
Biologically Relevant				Copy Number	TSC2	Deletion				0.0	0.0																					0				TSC2 Deletion		MEL-IPI_Pat02	MEL-IPI_Pat02-Tumor-SM-4DJZX	
Biologically Relevant				Copy Number	ERRFI1	Deletion				0.0	0.0																					0				ERRFI1 Deletion		MEL-IPI_Pat02	MEL-IPI_Pat02-Tumor-SM-4DJZX	
Biologically Relevant				Copy Number	JAK1	Deletion				0.0	0.0																					0				JAK1 Deletion		MEL-IPI_Pat02	MEL-IPI_Pat02-Tumor-SM-4DJZX	
Biologically Relevant				Microsatellite Stability	Supporting variants		JAK1 Deletion, PRDM2 p.E282del (Deletion), MSH3 p.AAAAAA52del (Deletion)																									0				Supporting variants: JAK1 Deletion, PRDM2 p.E282del (Deletion), MSH3 p.AAAAAA52del (Deletion)		MEL-IPI_Pat02		
Biologically Relevant				Mutational Signature	COSMIC Signature 7	version 2	0.653																									0				COSMIC Signature (version 2) 7 (65%)		MEL-IPI_Pat02		
